Managing non-proportionality of hazards (PH) within TNT: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple negative (TN) or brca1/2 breast cancer (BC)

Tovey, Holly; Bliss, Judith; Tutt, Andrew; Morden, James; Jarman, Katy; Martin, Sue; Kernaghan, Sarah; Toms, Christy; Kilburn, Lucy

doi:10.1186/1745-6215-16-S2-P150

Trials

Article metrics
Last updated: Fri, 26 Apr 2024 14:10:34 Z

Managing non-proportionality of hazards (PH) within TNT: a randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple negative (TN) or brca1/2 breast cancer (BC)

Access & Citations

973

Article Accesses
2

Web of Science
2

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1745-6215

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com